Author: Fan Shenghua Kelly
Publisher: Taylor & Francis Ltd
ISSN: 1054-3406
Source: Journal of Biopharmaceutical Statistics, Vol.19, Iss.3, 2009-05, pp. : 509-523
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Combination therapy of two antitumor agents may provide treatment additivity or synergy. Phase I trials for combination therapy search for the maximum tolerated dose (MTD) for combined agents. The conventional approach is to preselect an escalation path, usually increasing the dose of one agent and then another, and to use the standard 3 + 3 design. However, this procedure may miss the optimum dose combination, prolong the time it takes, and increase the number of patients necessary to reach the MTD. In this study, we present strategies for a comprehensive search for MTD for a two-agent combination therapy. We evaluate algorithms based on two-stage and three-stage design as well as variations in cohort size. A two-dimensional isotonic estimation method for toxicity rate is provided. We use simulation methods to compare 2 + 1 + 3 vs. 3 + 3 cohort sizes. We conclude that the comprehensive search proposed in our study can be more practical and efficient in identifying the MTD in combination-therapy of two agents.
Related content
OASIS-HT: design of a pharmacogenomic dose-finding study
By Staessen Jan A Kuznetsova Tatiana Acceto Rok Bacchieri Antonella Brand Eva Burnier Michel Celis Hilde Citterio Lorena de Leeuw Peter W Filipovský Jan Fournier Albert Kawecka-Jaszcz Kalina Manunta Paolo Nikitin Yuri O’Brien Eoin T Redón Josep Thijs Lutgarde Ferrari Patrizia Valentini Giovanni Bianchi Giuseppe
Pharmacogenomics, Vol. 6, Iss. 7, 2005-10 ,pp. :